Incyte Corporation
Clinical trials sponsored by Incyte Corporation, explained in plain language.
-
New hope for Hard-to-Treat lymphoma: modified drug combo shows promise
Disease control OngoingThis study tests a modified dosing schedule of the drug tafasitamab combined with lenalidomide in people with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who have had 1 to 3 prior treatments and cannot have a stem cell transplant. The main goal is to check the sa…
Phase: PHASE1, PHASE2 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated May 05, 2026 11:56 UTC
-
New hope for aggressive lymphoma: drug combo shows promise in large trial
Disease control OngoingThis study tests whether adding two drugs, tafasitamab and lenalidomide, to standard chemotherapy (R-CHOP) helps people with a fast-growing type of lymphoma called DLBCL. About 900 patients with high-risk, newly diagnosed disease are taking part. The goal is to see if the new com…
Phase: PHASE3 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Apr 30, 2026 15:50 UTC